Innovative Vaccine Platform Tiba Biotech has developed a novel dendrimer nanoparticle delivery platform for RNA vaccines and therapeutics, offering a unique opportunity to collaborate on next-generation vaccine development with organizations seeking advanced delivery technologies.

Strong Funding Backing With notable investments from the Gates Foundation and recent NIH funding, Tiba demonstrates robust financial support, indicating potential for partnership in funded research projects and contract manufacturing opportunities.

Strategic Partnerships Tiba's collaborations with research institutions and government agencies, including the US Army and NSW Government, position it as a trusted partner for tailored vaccine solutions and joint development programs across public health sectors.

Preclinical Innovation As a preclinical stage company with ongoing development of RNA vaccines against diseases like influenza and foot and mouth disease, Tiba offers opportunities for early-stage collaborations, licensing deals, or technology licensing to enhance existing vaccine pipelines.

Regional Expertise Headquartered in Cambridge with ties to MIT and Whitehead Institute, Tiba is well-positioned geographically to serve North American biotech markets and establish strategic alliances with biotech firms seeking cutting-edge RNA delivery platforms.